The SAKK is presenting this year's SAKK Trial Award with a grant of CHF 1 million to Prof. Dr. med. Christian Fankhauser from Lucerne Cantonal Hospital for conducting a Phase II clinical trial on the treatment of castration-resistant prostate cancer with a high dose of testosterone and a PARP-1 inhibitor (ISOTONIC trial). This trial examines the effectiveness of high doses of testosterone (HAT) in combination with a PARP-1 inhibitor in metastatic castration-resistant prostate cancer.

This highly endowed prize is being awarded for the second time. The prize money of CHF 1 million is of central importance for clinical oncological research in Switzerland.

The winning team

Prof. Dr. med. Christian Fankhauser, MD MPH

Specialist in urology, specializing in surgical urology FMH

Clinic for Urology, Lucerne Cantonal Hospital

The team was supported by the SAKK Project Group Urogenital

Project title

A phase II trial of High-dose Androgen Therapy (HAT) and PARP-inhibition in castration resistant prostate cancer patients progressing after novel androgen therapy (ISOTONIC)